Background-The human 9p21.3 chromosome locus has been shown to be an independent risk factor for atherosclerosis in multiple large-scale genome-wide association studies, but the underlying mechanism remains unknown. We set out to investigate the potential role of the 9p21.3 locus neighboring genes, including Mtap, the 2 isoforms of Cdkn2a, p16Ink4a and p19Arf, and Cdkn2b, in atherosclerosis using knockout mice models. Methods and Results-Gene-targeted mice for neighboring genes, including Mtap, Cdkn2a, p19Arf, and Cdkn2b, were each bred to mice carrying the human APO*E3 Leiden transgene that sensitizes the mice for atherosclerotic lesions through elevated plasma cholesterol. We found that the mice heterozygous for Mtap developed larger lesions compared with wild-type mice (49623Ϯ21650 versus 18899Ϯ9604 m 2 per section [meanϮSD]; Pϭ0.01), with morphology similar to that of wild-type mice. The Mtap heterozygous mice demonstrated changes in metabolic and methylation profiles and CD4 ϩ cell counts. The Cdkn2a knockout mice had smaller lesions compared with wild-type and heterozygous mice, and there were no significant differences in lesion size in p19Arf and Cdkn2b mutants compared with wild type. We observed extensive, tissue-specific compensatory regulation of the Cdkn2a and Cdkn2b genes among the various knockout mice, making the effects on atherosclerosis difficult to interpret. Conclusions-Mtap plays a protective role against atherosclerosis, whereas Cdkn2a appears to be modestly proatherogenic. However, no relation was found between the 9p21 genotype and the transcription of 9p21 neighboring genes in primary human aortic vascular cells in vitro. There is extensive compensatory regulation in the highly conserved 9p21 orthologous region in mice. (Circulation. 2012;126:1896-1906.)
T he 9p21.3 region of the genome has been identified as the locus with strongest association to coronary artery disease and myocardial infarction in multiple independent largescale genome-wide association studies. [1] [2] [3] The locus is within a 58-kb region that is devoid of protein coding genes, suggestive of a regulatory function ( Figure 1 ). Interestingly, the neighboring genes in the region include well-known tumor suppressor genes, eg, CDKN2A and CDKN2B. 4 -6 The CDKN2A locus encodes a cyclin-dependent protein kinase (CDK) inhibitory protein, p16INK4A, and a p53-regulatory protein, p19ARF. The CDKN2B gene encodes another CDK inhibitory protein, p15INK4B. Another gene in the region is methylthioadenosine phosphorylase (MTAP), which encodes a ubiquitously expressed metabolic enzyme, S-methyl-5Ј-thioadenosine phosphorylase, 7 that processes the polyamine biosynthesis byproduct in the methionine salvage pathway. Loss or inactivation of MTAP has frequently been observed in a number of different human tumors, and it has been shown to have a tumor suppressive role in a mouse model. 8 
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Multiple studies have demonstrated a potential role for cell-cycle regulatory mechanisms in atherosclerosis progression. Previously, the master tumor suppressor gene p53 has been implicated in the development of atherosclerosis in apolipoprotein E (ApoE)-null mice, 9,10 affecting both cell proliferation and apoptosis within the atheroma. Another tumor suppressor gene, p21Waf1, was also shown to increase the atheroma size in ApoE-null mice, 11 whereas the tumor suppressor p27Kip1 was shown to protect against atherosclerosis. 12 Correlations of the 9p21 locus single-nucleotide protein genotype to differential expression of the neighboring genes have been observed in several studies with inconsistent findings. [13] [14] [15] A knockout (KO) mouse model involving the entire region orthologous to the 9p21.3 coronary artery disease locus showed significant decreases in the expressed levels of Cdkn2a and Cdkn2b and increased proliferation of primary smooth muscle cells and mouse embryonic fibroblasts, although an effect on atherosclerosis in vivo was not demonstrated. 16 Mice deficient in the p19Arf gene were found to have increased atherosclerotic lesions in an ApoE-null background with significant attenuation of apoptosis in lesions, as well as in cultured primary macrophages and vascular smooth muscle cells. 17 To date, however, no observation on atherosclerotic phenotype has been made involving the other neighboring genes.
We set out to survey the 9p21.3 orthologous region using KO mice models to systematically address the role of the neighboring protein-coding genes in atherosclerosis. We chose the APOE*3 Leiden-sensitizing model because it is dominant, simplifying the construction of the models, and because it exhibits relatively modest elevations of cholesterol, more realistically modeling the human disease than other widely used models.
Methods
Detailed methods can be found in the online-only Data Supplement. Primers used for the genotyping and quantitative polymerase chain reaction assays are listed in Table I in the online-only Data Supplement.
Mice
All mouse protocols were approved by the UCLA Animal Review Committee. APOE*3 Leiden transgenic mice maintained on a C57BL/6 background were obtained from TNO (Leiden, Netherlands) 18 and rederived at the UCLA Division of Laboratory Animal Medicine. The Cdkn2a KO mice 4 and the p19Arf KO mice 5 were obtained from the National Cancer Institute Mice Repository and rederived at UCLA. The Cdkn2a KO mice were generated by targeted KO of exons 2 and 3 of the Cdkn2a gene, which are shared by both isoforms of the Cdkn2a gene, p16Ink4a and p19Arf. For the p19Arf KO mice, the alternate reading frame of p19Arf gene was selectively mutated; hence, the expression of p16Ink4a isoform was maintained ( Figure 1 ). Both strains were created on a mixed background of 129/Sv and C57BL/6 and then backcrossed to the C57BL/6 for Ͼ5 generations.
The Cdkn2b KO mice were a generous gift from the Licia Selleri laboratory at Cornell University. They were originally derived from the Barbacid laboratory in Spain. 6 For the Cdkn2b KO mice, the second exon of Cdkn2b gene was replaced with a Neo r cassette using 129/Sv DNA and then transfected to CJ7 embryonic stem cells (Figure 1 ). The embryonic stem cells were then injected into C57BL/6 blastocysts and subsequently bred to C57BL/6 mice for Ͼ5 generations.
The KO mice for each strain were initially bred to APOE*3 Leiden mice to generate F1 mice heterozygous for the mutation. F1 mice were mated with each other so that one of the pair carried the Leiden transgene. The F2 generation resulted in homozygous KO mice, wild-type (WT) mice, and heterozygous mice. Only female mice carrying the APOE*3 Leiden transgene were selected for the atherosclerosis study.
The Mtap heterozygous mice were derived at UCLA with embryonic stem cells (Mtap Gt(RRK081)Byg ) obtained from the Mutant Mouse Regional Resource Center at UC Davis. Briefly, a gene-trap vector encoding the En2 splice acceptor site fused to ␤-galactosidase/neo fusion gene was inserted between exons 3 and 4 of the mouse Mtap locus. These mice were maintained on a CBA/Ca background. Mice homozygous for the Mtap mutation are embryonic lethal, so the heterozygotes were mated with APOE*3 Leiden mice, and the resulting WT and heterozygote female mice carrying the APOE*3 Leiden transgene were selected for the atherosclerosis study.
Diet
A custom diet consisting of 1% cholesterol and 33 kcal% fat from mostly cocoa butter was prepared from Research Diets, Inc (product No. D10042101). The mice were put on the diet between 6 and 8 weeks of age and kept on it for 16 weeks before being euthanized for specimen collection.
Global Metabolic Profiling Assay
Freshly extracted liver tissue (100 g) was flash-frozen and sent to Metabolon, Inc (Durham, NC) for extraction and analysis. 19 The platform for sample analysis has been described in detail. 20 
Global Methylation Pattern Analysis
We obtained genomic DNA from liver tissue from Mtap heterozygous and WT male mice of 32 weeks of age and used reduced representation bisulfite sequencing to examine Ϸ1% of the genome, comprising sequences enriched in CpG. 21 To determine sites that were differentially methylated between the 2 samples, we constructed a confidence interval for the percent methylation level of each site using the binomial distribution (binofit in MATLAB). We called sites differentially methylated between the 2 samples if the percent methylation level of each sample was outside the 95% confidence interval.
Statistical Analysis
Two-group comparisons were made with the Welch modified t test if they met normality by the Kolmogorov-Smirnov test and further evaluated by both bootstrapping and permutations 22 at the ␣ϭ0.05 level if the Welch test was significant (see the online-only Data Supplement). All 3-group comparisons were performed with the nonparametric Kruskal-Wallis ANOVA test, followed by a pairwise comparison using the Dunn posttest if found to have a significant Kruskal-Wallis test.
Results

Baseline Characteristics of Mice
The baseline characteristics, including age, weight, fasting plasma lipids, fasting glucose, and body weight composition, are shown in the Table for all groups from each strain studied. There were no statistically significant differences in weight, lipid profile, and body composition (by nuclear magnetic resonance) results between the groups within each strain. A significant difference was observed in the fasting glucose levels in the Cdkn2a and p19Arf mutants compared with their respective WT groups (Pϭ0.001 and Pϭ0.007, respectively).
Effect of Mtap Gene Modulation on Atherosclerosis
Mtap WT and Mtap heterozygous mice on an APOE*3 Leiden background were compared for aortic lesion development and other characteristics (Mtap KO are not viable). No significant differences in the baseline weight or lipid levels were observed (Figure 2 ), and other baseline characteristics, including fasting glucose, insulin levels, and body fat composition, were also comparable (the Table) . As expected, the Mtap mRNA expression level was approximately halved in the heterozygous mice compared with the WT mice. A significant increase in the aortic sinus lesion size was observed in the heterozygotes compared with the Mtap WT mice ( Figure  2 ). No significant difference in the expression level of the 2 Cdkn2a isoforms, p16Ink4a and p19Arf, or Cdkn2b was seen between the 2 groups ( Figure I in the online-only Data Supplement). The sections obtained from the aortic sinus were subjected to immunostaining with antibodies against CD68. Staining showed the lesions to contain Ͼ90% CD68 ϩ cells in both Mtap WT and Mtap heterozygous mice (Figure 2) . A minority of cells in the lesions stained for smooth muscle actin and Mason trichrome, and there was no difference in the staining pattern between the WT and heterozygous mice (data not shown).
MTAP Deficiency Affects Metabolic Pathways, Global Methylation Dosage, and Peripheral T-Cell Composition
We examined the global metabolomics profiles of liver samples from a group of Mtap heterozygous mice compared with WT controls (nϭ3 each) using the Metabolon, Inc platform. Table II in the online-only Data Supplement lists the metabolites assayed in these samples and the raw expression values in each sample.
Mtap heterozygous mice generally had trends toward lower levels of metabolites involved in the methionine processing pathway, including S-adenosylmethionine, S-adenosylhomocysteine, and 5-methythioadenosine. Plasma from Mtap WT and Mtap heterozygous mice was assessed for total plasma homocysteine levels. However, no significant difference was found between the 2 groups (WT, 4.64Ϯ0.55 mol/L; heterozygous, 4.43Ϯ0.45 mol/L [meanϮSD]). Interestingly, taurine, a cysteine metabolite, was significantly decreased (0.6-fold) in the Mtap heterozygous mice compared with the WT mice.
Given the role of 5-methythioadenosine as a major methyl donor, we compared the global methylation pattern between the WT and heterozygous mice at a single-base methylome level. There was a significant difference in the genome-wide percent methylation levels: 5565 sites had a significant difference in methylation level on binomial distribution test, with Ͼ2000 sites showing Ͼ20% change in methylation levels ( Figure II in the online-only Data Supplement).
We also compared complete blood counts using the HemaTrue Hematology analyzer device (Heska) in Mtap heterozygous compared with control mice (nϭ3 versus 3). We noted no changes in counts of red blood cells, hemoglobin content, platelets, and white blood cells, including lymphocytes, monocytes, and granulocytes (Data not shown). Further analysis of the white blood cell population with fluorescence-activated cell sorter analysis of the peripheral blood showed that there was a significant decrease in the level of CD4 ϩ T cells in the MTAP heterozygous mice compared with the WT mice (11.8Ϯ4.0 versus 32.9Ϯ13.2% CD4 ϩ CD3 ϩ leukocytes; PϽ0.05). There was no significant difference in 
Effect of Cdkn2a Deficiency on Atherosclerosis
Three groups, including Cdkn2a WT, heterozygous, and KO mice, all on an APOE*3 Leiden background, were compared. There were no statistically significant differences in weight, body fat composition by nuclear magnetic resonance, and plasma lipid levels (the Table and Figure IV in the onlineonly Data Supplement). There was a significant difference in the plasma glucose level between the 3 groups; the heterozygous group had higher levels than the rest. The expression levels of the 9p21 orthologous genes showed decreased p19Arf and p16Ink4a expression, as expected, although p16Ink4a was maintained at similar levels in the heterozygotes and WT mice ( Figure V in the online-only Data Supplement). Unexpectedly, Cdkn2b and Mtap expression levels were inversely correlated to the Cdkn2a deletion status (Figure 3 ). The KO mice had decreased aortic sinus lesion size compared with the WT and heterozygous mice (Figure 3) , suggesting a recessive model of inheritance. Immunostaining of the frozen sections with CD68 showed that the lesions were predominantly macrophage in content (Figure 3) .
Effect of p19Arf Deficiency on Atherosclerosis
Three groups, p19Arf WT, heterozygous, and KO, were compared. There were no significant differences in lesion sizes between all 3 groups on an APOE*3 Leiden background (Figure 4) . A similar reciprocal trend in Cdkn2b expression was seen as in the Cdkn2a mutant mice, but there was also significant overexpression of p16Ink4a in the KO mice group in all 3 tissues examined ( Figure 4 and Figure VI in the online-only Data Supplement). There were no differences between the 3 groups in weight, plasma lipids, fat percent by weight, and spleen weight, although the fasting glucose levels were significantly lower in the KO group compared with heterozygotes (Pϭ0.009; the Table) . Interestingly, the reciprocal activation of the Cdkn2b gene was seen only in the liver and resident peritoneal macrophages, not in the aorta, demonstrating a tissue-specific cisregulatory mechanism within the region. The Mtap level was increased in the heterozygotes compared with both the WT and the KO mice ( Figure 4 and Figure VI in the online-only Data Supplement). We examined the expression levels for 36B4 in the aorta samples from p19Arf WT versus KO. There was no significant change in the average Cp between the 2 groups, suggesting that the changes noted in gene expression are not the result of a difference in the population of cells within lesions of these aorta samples (data not shown).
Effect of Cdkn2b Deficiency on Atherosclerosis
The 3 groups, Cdkn2b WT, heterozygous, and KO, were generated from the same littermates and compared. No differences in baseline characteristics were observed, including weight at the start or end of a high-cholesterol diet, lipid profile, fasting glucose, and fat percent by weight (the Table) . There were no differences in aortic sinus lesion sizes among the 3 groups ( Figure 5) . Again, the expression levels of the neighboring 9p21 orthologous genes were modulated in a compensatory and tissue-specific fashion. We observed that the p16Ink4a and p19Arf expression levels were increased in the KO mice in the peritoneal macrophages but not in the aorta ( Figure 5 ). There was a trend toward a difference in the Mtap expression in liver; however, an opposite relationship was observed in liver and aorta ( Figure 5 ).
Correlation of 9p21 Haplotype With 9p21 Neighboring Gene Expression in Primary Cell Culture
Using primary human aortic smooth muscle cells from 79 donors, we searched for any correlation between the 9p21 genotype (rs4977574) and the expression levels of the 9p21 neighboring genes ( Figure VII in the online-only Data Supplement). No significant correlation was found. In addition, we did not find any expression quantitative trait loci that mapped to the 9p21 region using an already published data set generated from primary human aortic endothelial cells. 23 
Discussion
We have explored the effects of the multiple protein coding genes near the 9p21 coronary artery disease locus on athero- There was no significant difference among the 3 groups (PϭNS). B, Aortic sinus lesion size. There was no significant difference among the 3 groups (PϭNS). C and D. p16Ink4a (left) and Cdkn2b (right) expression levels in aorta and resident peritoneal macrophages, respectively. There was a significant increase in p16Ink4a level with p19Arf KO loss in both aorta (Pϭ0.016) and macrophages (PϽ0.0001).
sclerosis in a hypercholesterolemic murine model. To the best of our knowledge, this is the first report that systematically describes the effect of these neighboring genes on atherosclerosis, including p16Ink4a, p19Arf, Cdkn2b, and Mtap. These included assessment of each of the genes on atherosclerosis and the identification of complex regulatory interactions of the neighboring tumor suppressor genes. Several novel conclusions emerged.
Mtap gene expression clearly conferred a protective phenotype against diet-induced atherosclerosis. Deficiency of the Mtap gene did not affect any of the other 9p21 neighboring genes, unlike other genes in the region that showed significant levels of compensatory modulations, suggesting that the effect on lesion size was due solely to the difference in Mtap expression levels.
Little is known about the function of Mtap gene product. One study found Mtap heterozygous mice to have a propensity to develop T-cell lymphoma, acting as a tumor suppressor. 8 MTAP is the first enzyme in a salvage pathway that allows reuse of sulfur from 5-methythioadenosine (a byproduct of the polyamine biosysnthetic pathway) for methionine biosynthesis. The exact mechanism is unclear, but the polyamine metabolism is known to affect cell-cycle regulation and apoptosis via the Akt/protein kinase B and Rb pathways, respectively. 24 A major pathway of methionine metabolism is the methylation pathway, which involves the conversion of methionine to S-adenosylmethionine, a universal methyl donor. During methylation reactions, S-adenosylmethionine is converted to S-adenosylhomocysteine, which is subsequently hydrolyzed to homocysteine. Total homocysteine levels have long been implicated in humans as an independent risk factor for atherosclerosis. 25, 26 The mechanism behind this association is unclear, but protein N-homocysteinylation, 27 changes in redox state, endothelial dysfunction, and smooth muscle cell proliferation have all been implicated. 28 To date, no studies have looked at whether the 9p21 risk locus was independent of the homocysteine levels in humans. Although we did not see any difference in the total plasma homocysteine levels between the Mtap WT and Mtap heterozygous mice, it is conceivable that a dynamic imbalance in the sulfur salvage for methionine biosynthesis is induced by the modulation in Mtap levels.
Indeed, further examination of the levels of metabolites using a global metabolite panel showed that there were perturbations in the levels of metabolites linked to the methionine and cysteine processing pathways. Overall, Mtap haploinsufficiency caused a decrease in metabolites upstream of this enzyme within the methionine salvage pathway in liver, plausibly as a result of feedback inhibition, and likely contributing to reduced levels of taurine (2-aminoethanesulfonic acid). Interestingly, taurine has previously been implicated in atherosclerosis. Taurine concentrations are very high in mammalian tissues, 29 including lymphocytes. There is evidence for a reduction in atherosclerosis in animal models after administration of taurine. 30 -32 Taurine is processed to taurine-chloramine, which is formed by reaction between taurine and neutrophil-derived hydroclorous acid, and there is evidence that both substances protect against oxidant stress, regulate inflammatory processes, and inhibit lymphocyte proliferation and cytokine production. 33, 34 Other evidence suggests that taurine may have a protective role by increasing T-regulatory cells, which are known to protect against atherosclerosis. 35 Future studies should include examination of taurine levels in different tissues, including plaques, and measurement of the cytokine levels involved with T-cell activation and nuclear factor-B pathways.
Interestingly, the choline metabolite trimethylglycine is a source of methyl groups for the synthesis of S-adenosylmethionine. 36 We have previously shown that serum choline, trimethylamine-N-oxide, and trimethylglycine (betaine) levels are positively correlated with atherosclerosis. 37 These data are of interest because we noted changes in metabolites of choline in Mtap heterozygous mice, although the levels of choline and betaine were not changed. These data suggest complex interactions between the MTAP pathway of methionine salvage, choline metabolism, and atherosclerosis.
A look at the global methylation pattern also showed a significant difference between the Mtap WT and heterozygous mice. These changes are consistent with the extensive role of the methionine processing pathway in methyl donation, although we saw both a significant increase or decrease in methylation levels at a large number of sites.
We also observed a significant decrease in the level of CD4 ϩ T lymphocytes in Mtap heterozygous mice compared with the WT mice. The Mtap heterozygous mice develop T-cell lymphomas at a higher incidence with increase in activated CD4
ϩ T-cell expansion beginning at Ϸ2 years of age. 8 In this study, the mice were young at the time of death, and there was no evidence of general lymphoproliferation.
Numerous studies have reported an association of low CD4 ϩ T-cell counts with increased incidence of cardiovascular events, especially in immunosuppressed or immunocompromised hosts. 38 -40 A potential explanation includes the role of T lymphocytes in inhibiting or modulating the vascular response to injury, protecting against atherogenesis. 41 Collectively, these data suggest several plausible mechanisms that could relate MTAP insufficiency to the pathogenesis of cardiovascular disease. In mice, homozygous deletion reveals a critical role for Mtap during the developmental process and suggests an important enzymatic activity. Further studies of these pathways may reveal interesting mechanisms linking MTAP and human CVD phenotype. These data also highlight the value of examinations of heterozygous-deficient mouse models with respect to proteins having critical functions. Further studies to investigate the effect of MTAP on pathways related to cell proliferation in tissues involved in atherosclerosis are warranted.
The involvement of the methionine and cysteine processing pathway also has implications in therapeutics. Deletion of MTAP in conjunction with CDKN2A has been observed frequently in different types of cancers, and treatment with toxic adenine analogs has been suggested on the basis of on in vitro experiments and mouse models. 42 Along the same line, a potential strategy would be to target cells with MTAP deficiency for therapy using toxic adenine analogs and 5-methythioadenosine. One report has also demonstrated treatment of mice with the MTAP inhibitor methylthio-DADMe-immucillin-A 43 and showed increased apoptosis and suppressed tumor growth. It would be of interest to examine the effects of this compound in a mouse model of atherosclerosis.
The KO of Cdkn2a also conferred protection against atherosclerosis despite the gene compensation from the other flanking genes, Cdkn2b and Mtap. The mechanism underlying this finding is unclear, but it appears to be independent of lipids, total body fat, and glucose. In the Cdkn2a KO mice, there was absence of both p16Ink4a and p19Arf expression; hence, it is difficult to conclude that the difference in lesion size seen between the WT/heterozygous and KO groups was due to p19Arf or p16Ink4a. However, there was sustained expression of the p16Ink4a level in the Cdkn2a heterozygous mice compared with the WT mice. A potential explanation includes that the decrease in p19Arf expression increased the expression of p16Ink4a, as suggested by Figure 4C . There was also a compensatory increase in Cdkn2b and Mtap expression levels (Figure 3) , further complicating the interpretation of which gene predominantly affects the phenotype. The Mtap level was unchanged or decreased in the p19Arf KO mice, suggesting that p16Ink4a has an inhibitory role against Mtap ( Figure VI in the online-only Data Supplement). Because the differences in end points are seen only in the KO group compared with the WT and heterozygous groups, as in the p16Ink4a expression levels, this may suggest that p16Ink4a expression is the primary driver of atherosclerosis. This hypothesis could potentially be tested with the use of an independent p16Ink4a KO system.
Our findings differ in some respects from the previously published study of Gonzalez-Navarro et al. 17 This study demonstrated increased atherosclerosis in p19Arf KO mice on an ApoE-null background compared with WT. The authors noted a decrease in apoptosis in lesions in the plaques of the p19Arf KO mice. We did not find any difference in p19Arf WT or KOs in our study with respect to atherosclerosis, a difference that may be attributable to background (ApoE null versus APOE*3 Leiden), diet (2.8% versus 1% cholesterol), or differences in total KOs examined (nϭ17 versus nϭ9) in the Gonzalez-Navarro study and the present study, respectively, despite the similar levels of total cholesterol among the mice in both studies. Of note, similar to Gonzalez-Navarro et al, we observed significant gene compensation of other flanking genes in our p19Arf KO model. 17 More recently, the same group published a study examining the role of Cdkn2a overexpression in transgenic ApoE-null mice. 44 Contrary to expectations, there was no difference in lesion size between the transgenic and WT mice. Our results showing no difference in lesion size between the Cdkn2a WT and heterozygous mice are consistent with these findings from the Cdkn2a transgenic study.
Interestingly, recent studies in human and human tissue culture cells have failed to demonstrate a consistent relationship between the levels of the genes flanking 9p21, the noncoding transcript ANRIL, and the 9p21 risk alleles, raising the possibility that these genes may not be involved at all. [13] [14] [15] 45 However, as noted, cell specificity may be important, and studies of cell-specific expression in macrophages, smooth muscle cells, and endothelial cells in atherosclerotic lesions have not been published to date. We have used primary cells extracted from the aorta of heart donors and did not find a correlation between 9p21 single-nucleotide proteins and the expression level of neighboring genes in aortic endothelial and smooth muscle cells. It is possible that the differences in expression of these genes with respect to the risk alleles may be subtle, requiring a much higher number of plaques studied to have statistical power to detect this difference. Finally, similar to genes active in the process of development, the expression of the genes flanking 9p21 may be more important during earlier time points than those measured in the aforementioned studies. Expression in chronic, late-stage plaques would therefore not reflect the significance of the role they play in the development of atherosclerosis.
Another novel observation in this study was the complexity of gene regulation that exists in this region. The Cdkn2a, p19Arf, and Cdkn2b mutations all showed little to no effect on atherosclerosis. Surprisingly, there was a significant compensatory modulation of the expression levels of the 9p21 orthologous genes in all strains except the Mtap mutant mice. This trend was observed in the liver and resident peritoneal macrophages, as well as in the aorta, but tissue-specific modulations were also observed in some cases. To the best of our knowledge, this is the first report to describe such an extensive reciprocal regulation within this region. One report suggested a potential inverse relation or lack of relation between the methylation pattern of promoters of p16Ink4a and Cdkn2b in cancers from an observational study. 46 p16Ink4a and Cdkn2b are both CDK inhibitory proteins that bind to the CDK4 and may explain such a redundancy. It is surprising that the functionally distinct protein p19Arf causes not only a significant overexpression of p16Ink4a (Ͼ20 fold) in its absence, as previously reported, 17 but also an increase in Cdkn2b (Ͼ3-fold). Given the complexity inherent in this locus and the modulation of the different neighboring genes, the effect on atherosclerosis of these individual genes is difficult to interpret. By inference, these findings suggest a mechanism to protect the critical function of this region. The high functional redundancy in this locus also points to the likelihood that the 9p21 risk locus affects a cis-regulatory element of this region that is critical for compensatory mechanism activated in response to stress.
The mechanism of this compensatory regulation is unclear but can potentially involve changes in methylation patterns, histone modification, and common binding motif to a transcription factor. It is interesting that the mutation status of the Cdkn2a, p19Arf, and Cdkn2b genes affected the Mtap gene expression levels as well, but not vice versa. The promoter region of Mtap is relatively distant from the promoter regions of Cdkn2a and Cdkn2b, at Ϸ200 kb, and this may suggest a trans effect such as a transcription factor-mediated overexpression as a more likely mechanism of this modulation. There were no statistically significant differences in the Cdkn2a and Cdkn2b genes between Mtap WT and heterozygotes, which allowed direct comparison of the effect of Mtap on atherosclerosis.
Conclusions
We identified the MTAP gene as a novel regulator of atherosclerotic lesion development potentially by modulating the methionine and cysteine processing pathways, the T lymphocytes, and the global methylation pattern. We also observed significant compensatory regulation of this region, which corroborates previous findings of dense regulatory components inherent to this locus. 47 Because of this compensatory regulation, the effects of the other genes in this locus, Cdkn2a, p19Arf, and Cdkn2b, were difficult to assess. However, despite this regulation, an effect of Cdkn2a on atherosclerosis was observed. Further studies are needed to define the regulation of the 9p21 genes and the mechanisms by which these genes modulate an effect on atherosclerosis.
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